* Anuh Pharma Limited has released its Investor Presentation for Q2 FY 2025-26. * The presentation covers H1 FY 2026 & H1 FY 2025 highlights, company overview, infrastructure, future outlook, and corporate social responsibility. * H1 FY 2025 Revenue was ₹376.73 crore compared to ₹310.98 crore in H1 FY 2024, a 21.14% increase. * EBITDA was ₹20.87 crore compared to ₹30.46 crore, a decrease of 31.47%. * PBT was ₹20.87 crore compared to ₹30.46 crore, a decrease of 31.47%. * Key operational updates include adding a new intermediate block, increasing effluent treatment capacity, and commissioning new solar power capacity. * R&D efforts are progressing in diabetic care, anticoagulant therapies, and anti-malarials. * The company has enhanced its capacity from 2200 MTPA to 2400 MTPA in 2025. * The company anticipates a steady growth rate of 15-16% per annum.
